

PARTNER PLATFORM
High Throughput Screening / Hit to lead

Chemogenomic and Biological Screening Core Facility (PF-CCB)

General information

Administrative information	
Structure	Institut Pasteur – CNRS (UMR 3523)
Address	25/28 rue du Dr. Roux 75724 Paris Cedex 15
Website	https://research.pasteur.fr/en/team/fabrice-agou-team/
Manager	Fabrice AGOU
Contact	fabrice.agou@pasteur.fr
Date of implementation	04/03/2016

Labels / quality approach	
IBiSA	Not yet
ISO 9001 certification	Not yet
National networks	GDR ChemBio
International networks	Specify
Other	Pasteur International Network

Team	
Number of researchers	2
Number of engineers	5
Number of technicians	2
Number of administrative staff	1
Other	2 (M2 students) 1 (PhD student), 2 (Post-Docs)

Main achievements	
Number of screenings performed since creation	35
Number of screenings performed per year	6
Fields of expertise / therapeutic areas	
Emerging infection disease, AMR, Host-directed therapies, Cancer, Neurodegenerative diseases	

Scientific Information

Chemical Library	
Description of the collection (number of chemical molecules, natural, royalty-free products, known synthesis methods, etc)	
130 k small molecules (see a more detailed description on https://research.pasteur.fr/en/team/fabrice-agou-team/)	
Conditioning	Acoustic 384-well plates in DMSO
Database (structure, accessibility conditions)	Access through a CDD Vault software implemented in house
Member of the National Chemical Library	Yes

Targets	
Targets for the screening service (e.g. protein targets, cell targets, etc.)	
Multiple pure targets (protein, nanobody, antibody and RNA), cell lines and multi-lineage organoids.	
Activities (e.g. cloning, protein expression, obtaining cell lines, management and storage of lines, cell culture, etc.)	
Development, management and storage of reporter cell lines, cloning, expression and purification of recombinant proteins, nanobodies and antibodies in bacteria and mammalian cells, <i>in vitro</i> transcription and purification of long coding RNA, cell culture under BSL2 and BSL3 conditions	

High throughput screening	
Number of measurements/days (approx.)	1000-4000 depending on the assay
Biological tests proposed (e.g. <i>in vitro</i> enzymatic tests, cell tests (binding tests, cell survival, image analysis, etc)	
Development and execution of multiple target-, cell- and imaging-based screening assay, including pilot screening project, primary screening campaign and orthogonal assay. <i>In cellula</i> and <i>in vivo</i> screening activities for cancer projects as well as for some antiviral projects under BSL2 and BSL3 conditions (SARS-CoV-2, Yellow Fever, Dengue and Chikungunya). Preclinical studies proposed in rodent models including mouse, rat and hamster.	
Technologies / Equipment (robots, automats, etc.)	
A detailed description of all equipment, automats and robots can be found on : https://research.pasteur.fr/en/team/fabrice-agou-team/	

Access	
Site teams	Yes
External academic teams	Yes
Private Outdoor Teams	Yes

Training courses offered
Training courses on multiple instruments (multimodal microplate reader, Octet HTX, Creoptix WaveCore, Tycho nanotemper NT6, DynaPro plate reader II and fluorescence microscopes) as well as assay development and execution for HTS and HCS projects can be offered by specialist engineers